StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) stock

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$170.26+2.68 (+1.60%)

Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%

Gilead Sciences pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Gilead Sciences's pe ratio was 17.7× on Jul 31, 2026, against 23.8× a year earlier. Over the last 5 years it ranged from 11.7× to 300.8×, with a median of 19.4×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 202617.7×−1.4
2025Dec 31, 202519.1×−89.2
2024Oct 31, 2024108.3×+90.9
2023Dec 29, 202317.4×−15.0
2022Dec 30, 202232.4×+20.0
2021Dec 31, 202112.4×−47.7
2020Dec 31, 202060.1×+29.0
2019Dec 31, 201931.1×−21.0
2018Dec 31, 201852.1×+44.0
2017Dec 29, 20178.2×+1.5
2016Dec 30, 20166.6×−2.6
2015Dec 31, 20159.3×−7.4
2014Dec 31, 201416.6×−24.4
2013Dec 31, 201341.0×+18.1
2012Dec 31, 201223.0×+11.1
2011Dec 30, 201111.9×+0.3
2010Dec 31, 201011.6×−5.3
2009Dec 31, 200916.9×–

More Gilead Sciences figures

See a number that looks wrong?